The CEO and president of ImmunoPrecise Antibodies LTD, Dr. Jennifer Bath directs an Austin, Texas enterprise that accelerates AI-driven discovery of novel therapeutics. Her company provides proprietary solutions that accelerate innovation through AI native software driven analyses based on pattern recognition. Dr. Jennifer Lynne Bath and her team also provide innovative antigen design, modeling, and production solutions. She has raised more than $200 million in capital, and the acquisitions and integrations she has managed have spanned subsidiaries worldwide.
Dr. Jennifer Bath holds a PhD in cellular and molecular biology, focused on tropical diseases and vaccines. Her work involved preventing tropical diseases that have a disproportionate effect on children and other vulnerable people in developing areas of the globe. Dr. Bath has served as an associate professor at Concordia College and guided a research team as principle investigator. Her team focused on understanding host cell response immunomodulation as part of helminth chronic infections.
Dr. Jennifer Lynne Bath’s experience extends to a previous role informing strategic and operational business practices at Talem Biologics Co. She advanced solutions in the discovery of new vaccine and therapeutic antibody solutions, and emphasized staff training and education as ways of delivering best outcomes.